Passage Bio, Inc. PASG
4.00 USD +0.22 (+5.82%)
At closeNov 11, 2026, 4:00 PM EST
4.00 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
3.80 Day range 4.00
3.32 52-week range 19.85
- YTD
- -66.10%
- 1 year
- -48.05%
News
globenewswire.com $HAREHOLDER ALERT: The M&A Class Action Firm Launches Investigation for the Merger — BWMN, UTZ , PASG and FNWD NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders…
gurufocus.com MERGER VOTE ALERT: The M&A Class Action Firm Is Investigating the Merger Vote -- UTZ, SAFT, PASG and FNWD MERGER VOTE ALERT: The M&A Class Action Firm Is Investigating the Merger Vote -- UTZ, SAFT, PASG and FNWDPR NewswireNEW YORK, Oct. 25, 2026NEW YORK, Oct. 25, 20
gurufocus.com PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Passage Bio, Inc. (NASDAQ: PASG) and Remix Therapeutics, Inc. Upon closing of the
businesswire.com PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Passage Bio, Inc. (NASDAQ: PASG) and Remix Therapeutics, Inc. Upon closing of the proposed…
globenewswire.com $HAREHOLDER ALERT: IS IT A FAIR DEAL FOR YOU? The M&A Class Action Firm Is Investigating the Merger — UTZ, SAFT, PASG and FNWD NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and…
defenseworld.net Passage Bio, Inc. (NASDAQ:PASG) Stock Has Average Price Target of $13.25 According to Brokerages Shares of Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) have earned a consensus rating of "Hold" from the nine ratings firms that are covering the company, MarketBeat reports. One investment…
defenseworld.net Passage Bio (NASDAQ:PASG) Stock Falls 2.4% – Here’s What Happened Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) shares traded down 2.4% during mid-day trading on Friday. The stock traded as low as $3.61 and last traded at $3.69. Approximately 12,111 shares…
defenseworld.net Analysts Set Passage Bio, Inc. (NASDAQ:PASG) Price Target at $13.25 Shares of Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) have been assigned an average rating of "Hold" from the nine research firms that are currently covering the company, Marketbeat reports.…
benzinga.com Passage Bio Q2 EPS $(2.44) Beats $(3.47) Estimate Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(3.47) by 29.68 percent. This is a 17.57 percent increase over losses of $(2.96)…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne…
seekingalpha.com Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript- benzinga.com 9 Health Care Stocks Moving In Wednesday's After-Market Session Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-market session. The market value of their outstanding shares is at $9.7 million. Greenland Mines…
benzinga.com Passage Bio, Remix Therapeutics Sign All-Stock Business Combination Agreement; Combined Entity To Operate Under Remix Therapeutics, RMTX Ticker On Nasdaq Passage Bio, Inc. (Nasdaq: PASG) ("Passage Bio") and Remix Therapeutics, Inc. ("Remix"), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and…
globenewswire.com Passage Bio and Remix Therapeutics Announce Merger Agreement Combined company to operate as Remix Therapeutics and advance Remix's pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin
benzinga.com Chardan Capital Downgrades Passage Bio to Neutral, Lowers Price Target to $7 Chardan Capital analyst Janani Sundararajan downgrades Passage Bio (NASDAQ:PASG) from Buy to Neutral and lowers the price target from $21 to $7.
benzinga.com This Mohawk Industries Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday Wall Street analysts changed outlook for top names, including downgrading Mohawk Industries and Passage Bio. See analyst ratings for these stocks.- benzinga.com Oppenheimer Maintains Outperform on Passage Bio, Lowers Price Target to $15 Oppenheimer analyst Jay Olson maintains Passage Bio (NASDAQ:PASG) with a Outperform and lowers the price target from $30 to $15.
benzinga.com Wedbush Downgrades Passage Bio to Neutral, Lowers Price Target to $8 Wedbush analyst Yun Zhong downgrades Passage Bio (NASDAQ:PASG) from Outperform to Neutral and lowers the price target from $32 to $8.
benzinga.com Crude Oil Surges Over 6%; Investar Holding Shares Gain Following Q1 Earnings US stocks down at midday, Dow down 0.2%, NASDAQ down 0.52%. Energy up 1.1%, consumer discretionary down 1.2%. Investar beats earnings.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results US stocks mixed, energy shares climb. Cleveland-Cliffs falls 6% after reporting Q1 results. Enveric Biosciences, Fitness Champs, Clearmind Medicine surge.
benzinga.com Reported Earlier: Passage Bio Receives FDA Guidance Requiring Randomized Registrational Trial For PBFT02 in FTD-GRN, Evaluates Next Steps In Clinical Development Regulatory & Program UpdateThe Company has completed a Type C meeting with the FDA to seek guidance on key elements of a future registrational trial of PBFT02 for FTD-GRN patients. Based on the…
benzinga.com Reported Earlier: Passage Bio Initiates Strategic Review, Exploring Mergers, Acquisitions, Partnerships, And Other Options To Maximize Shareholder Value Corporate UpdateThe Company has initiated a review of strategic alternatives to maximize shareholder value. These strategic alternatives may include merger or acquisition transactions, a reverse…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Passage Bio Reports Updated Data From Ongoing Phase 1/2 upliFT-D Clinical Trial Evaluating PBFT02 For Treatment Of Frontotemporal Dementia With Granulin Mutations PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels FDA feedback from recent…
globenewswire.com Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Oppenheimer Initiates Coverage On Passage Bio with Outperform Rating, Announces Price Target of $30 Oppenheimer analyst Jay Olson initiates coverage on Passage Bio (NASDAQ:PASG) with a Outperform rating and announces Price Target of $30.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
defenseworld.net Analysts Set Passage Bio, Inc. (NASDAQ:PASG) PT at $42.67 Shares of Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the four ratings firms that are currently covering the stock, MarketBeat…- benzinga.com Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $23 Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $67 to $23.
- benzinga.com Passage Bio Q4 EPS $(4.09) Misses $(2.68) Estimate Passage Bio (NASDAQ:PASG) reported quarterly losses of $(4.09) per share which missed the analyst consensus estimate of $(2.68) by 52.5 percent. This is a 2.25 percent decrease over losses of $(4.00)…
globenewswire.com Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim…
globenewswire.com Passage Bio to Participate in Upcoming Investor Conferences PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative…
defenseworld.net Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67 Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been assigned an average rating of "Moderate Buy" from the four brokerages that are currently covering the stock, MarketBeat reports. One…
defenseworld.net Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Price Target at $42.67 Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been given an average rating of "Moderate Buy" by the four research firms that are currently covering the company, Marketbeat Ratings reports.…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
defenseworld.net Analyzing Passage Bio (NASDAQ:PASG) and Vir Biotechnology (NASDAQ:VIR) Passage Bio (NASDAQ: PASG - Get Free Report) and Vir Biotechnology (NASDAQ: VIR - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two…
defenseworld.net Financial Comparison: Passage Bio (NASDAQ:PASG) versus PepGen (NASDAQ:PEPG) Passage Bio (NASDAQ: PASG - Get Free Report) and PepGen (NASDAQ: PEPG - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based…
defenseworld.net Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67 Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been assigned an average rating of "Moderate Buy" from the four ratings firms that are covering the firm, Marketbeat Ratings reports. One…- benzinga.com Chardan Capital Maintains Buy on Passage Bio, Raises Price Target to $21 Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and raises the price target from $6 to $21.
benzinga.com Passage Bio Q3 EPS $(2.44) Beats $(2.80) Estimate Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.80) by 12.86 percent. This is a 60.33 percent increase over losses of $(6.15)…
globenewswire.com Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish…- benzinga.com Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $67 Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $260 to $67.
- benzinga.com Guggenheim Maintains Buy on Passage Bio, Lowers Price Target to $10 Guggenheim analyst Debjit Chattopadhyay maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $40 to $10.
benzinga.com Wedbush Maintains Outperform on Passage Bio, Raises Price Target to $40 Wedbush analyst Yun Zhong maintains Passage Bio (NASDAQ:PASG) with a Outperform and raises the price target from $3 to $40.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Passage Bio Q2 EPS $(2.96) Misses $(0.21) Estimate Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.96) per share which missed the analyst consensus estimate of $(0.21) by 1309.52 percent. This is a 41.85 percent increase over losses of…